Download full-text PDF |
Source |
---|
Cureus
December 2024
Nephrology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus.
View Article and Find Full Text PDFBalkan Med J
January 2025
Department of Clinical Pharmacy, China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, China.
Toxins (Basel)
December 2024
Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Pain is a frequent and disturbing symptom among hemodialysis patients. Protein-bound uremic toxins (PBUTs) are related to cardiovascular and overall mortality, and they are difficult to remove with current hemodialysis treatments. The PBUT displacers, such as furosemide, tryptophan, or ibuprofen, may be promising new strategies for improving their clearance.
View Article and Find Full Text PDFCureus
November 2024
Department of Therapeutic Processes, Faculty of Health Sciences, Universidad Católica de Temuco, Temuco, CHL.
Background: Contradictory data are available on the possible association between sarcopenia and other clinical disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis.
Objective: To determine the association between sarcopenia and markers associated with systemic inflammation, fasting glycemia, and quality of life in older people with CKD undergoing hemodialysis.
Methods: This was an analytical cross-sectional study.
Cureus
October 2024
Internal Medicine, Tbilisi State Medical University, Tbilisi, GEO.
Numerous studies have shown that dialysis may not be as beneficial to elderly, frail patients with chronic kidney failure and multiple comorbidities as comprehensive conservative therapy (CCT) and that dialysis may worsen the quality of life (QOL), increase hospitalization rates, and cause a significant decline in functional status. Several mortality predictors have been proposed to determine which patients would benefit more from CCT or dialysis. We estimated the short-term risk of death in an 81-year-old male patient with kidney failure and highly severe frailty using the REIN score, a dependable risk prediction model proposed by the European Renal Best Practice Group for the prediction of short-term risk mortality.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!